A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysisCapsule Summary

• Главные авторы: Norito Katoh, MD, PhD (Автор), Yukihiro Ohya, MD, PhD (Автор), Hiroyuki Murota, MD, PhD (Автор), Masanori Ikeda, MD, PhD (Автор), Xiaofei Hu, PhD (Автор), Kimitoshi Ikeda, PhD (Автор), John Liu, MD, MS (Автор), Takuya Sasaki (Автор), Alvina D. Chu, MD (Автор), Henrique D. Teixeira, PhD, MBA (Автор), Hidehisa Saeki, MD, PhD (Автор)
• Формат: ‌
• Опубликовано: Elsevier, 2022-03-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Background: Systemic atopic dermatitis treatments that have acceptable safety are needed. Objective: To evaluate the safety of the oral Janus kinase inhibitor upadacitinib in combination with topical corticosteroids (TCSs) for the treatment of atopic dermatitis. Methods: In this phase 3, double-blin...